All Updates

All Updates

icon
Filter
Partnerships
Numinus partners with MAPS to offer psychedelic experiential opportunities for practitioners
Psychedelic Medicine
Jun 15, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Psychedelic Medicine

Psychedelic Medicine

Jun 15, 2023

Numinus partners with MAPS to offer psychedelic experiential opportunities for practitioners

Partnerships

  • Canadian psychedelic company Numinus Wellness partnered with the Multidisciplinary Association for Psychedelic Studies (MAPS) to support psychedelic experiential opportunities for practitioners within a clinical study.

  • Pending approval of its Clinical Trial Application (CTA) by Health Canada, Numinus will have exclusive rights to conduct a clinical trial for practitioners interested in MDMA-assisted therapy. The trial will allow practitioners to observe and participate in MDMA sessions to enhance their understanding of psychedelic-assisted therapy. 

  • The clinical trial will employ clinical-grade MDMA manufactured by Optimi, a licensed Canadian company specializing in producing and supplying psychedelic substances for clinical trials. Initially, Numinus intends to conduct the trial at its clinics in Vancouver, with potential expansion to other locations in the future.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.